Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components (Tables)

v3.22.2.2
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Components of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

September 30,

2022

 

 

December 31,

2021

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

1,061

 

 

$

794

 

Clinical trial related costs

 

 

830

 

 

 

1,134

 

Non-clinical research and manufacturing operations

 

 

2,691

 

 

 

2,153

 

Payroll related

 

 

4,254

 

 

 

5,388

 

Other accrued expenses

 

 

54

 

 

 

46

 

Total Accrued liabilities

 

$

8,890

 

 

$

9,515